Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study

Pellesi, Lanfranco; Al‐Karagholi, Mohammad Al‐Mahdi; Icco, Roberto De; Chaudhry, Basit Ali; López, Cristina López; Snellman, Josefin; Hannibal, Jens; Amin, Faisal Mohammad; Ashina, Messoud

doi:10.3389/fneur.2022.871176

Cited by 10 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a positive correlation between serum CGRP levels and pain intensity was also reported [ 41 ]. It must, however, be noted that other studies did not report any changes in CGRP levels among EM and CM patients [ 42 , 43 , 44 , 45 , 46 ].…”

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 82%

“…Changes in peripheral CGRP levels have also been found in animal migraine models based on the electrical stimulation of the superior sagittal sinus, trigeminal ganglion, or dura mater, in an animal model of intracisternal inflammatory soup and in mice with RAMP-1 deficiency [ 57 , 58 , 59 , 60 , 61 , 62 ]. By contrast, experimental human models (e.g., hypoxia and VIP infusion) did not report any significant change in CGRP blood plasma levels in migraine patients [ 46 , 63 ]. Finally, in both human and animal models, the increased CGRP levels were reduced by migraine treatments [ 55 , 56 , 60 , 64 ].…”

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

“…In patients with EM, VIP causes migraine attacks 2 h after its infusion, suggesting an important role in migraine pathophysiology [ 97 ]. Increased plasma levels of CGRP were found in EM before the onset of migraine attacks but were unrelated to the occurrence of VIP-triggered migraine attacks [ 46 ]. The continuous intravenous infusion of VIP over two hours causes delayed mild headaches in HC, as well as long-lasting cranial vasodilation and activation of the cranial parasympathetic system [ 95 , 96 ].…”

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Demartini

Francavilla

Zanaboni

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

In recent years, numerous efforts have been made to identify reliable biomarkers useful in migraine diagnosis and progression or associated with the response to a specific treatment. The purpose of this review is to summarize the alleged diagnostic and therapeutic migraine biomarkers found in biofluids and to discuss their role in the pathogenesis of the disease. We included the most informative data from clinical or preclinical studies, with a particular emphasis on calcitonin gene-related peptide (CGRP), cytokines, endocannabinoids, and other biomolecules, the majority of which are related to the inflammatory aspects and mechanisms of migraine, as well as other actors that play a role in the disease. The potential issues affecting biomarker analysis are also discussed, such as how to deal with bias and confounding data. CGRP and other biological factors associated with the trigeminovascular system may offer intriguing and novel precision medicine opportunities, although the biological stability of the samples used, as well as the effects of the confounding role of age, gender, diet, and metabolic factors should be considered.

show abstract

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 82%

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Demartini

Francavilla

Zanaboni

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…episodic migraine patients (10). Regarding (a), we used a mixedeffect model to evaluate any change in plasma VIP during PACAP and VIP days.…”

Section: Discussionmentioning

confidence: 99%

Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundPituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks.MethodsParticipants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T0, T20, T30, and T90. Plasma levels of VIP were measured using a validated radioimmunoassay method.ResultsBlood samples were collected from participants with episodic cluster headache in the active phase (eCHA, n = 14), remission (eCHR, n = 15), and from participants with chronic cluster headache (cCH, n = 15). Baseline levels of VIP did not differ among the three groups (p = 0.1161). During PACAP infusion, mixed-effects analysis revealed a significant increase in plasma levels of VIP in eCHA (p = 0.0300) and eCHR (p = 0.0058) but not in cCH (p = 0.2930). We found no difference in the increase of plasma VIP levels between patients who developed PACAP38- or VIP-induced attacks.ConclusionCluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache.Clinical trial registrationThe parent study is registered at ClinicalTrials.gov (NCT03814226).

show abstract

“…This has not been consistently reproducible. 50 While not completely reproducible, patients with chronic migraine have elevated CGRP between migraine attacks relative to patients with episodic migraine and individuals without migraine. 51,52 A decrease in CGRP levels has been observed after migraine episodes in patients who are treated with a triptan medication.…”

mentioning

confidence: 99%

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine

Root¹,

Ahn²,

Kirsch³

et al. 2023

NDT

View full text Add to dashboard Cite

Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were the first class of medication specifically developed for the prevention of migraine. Fremanezumab is one of four CGRP mAbs currently available and is approved by the US Food and Drug Administration (FDA) for the preventative treatment of episodic and chronic migraines. This narrative review summarizes the history of fremanezumab development, the trials that led to its approval, and the later studies published evaluating its tolerability and efficacy. Evidence of fremanezumab for clinically significant efficacy and tolerability in patients with chronic migraine is especially important when considering the high level of disability, lower quality of life scores, and higher levels of healthcare utilization associated with this condition. Multiple clinical trials demonstrated superiority of fremanezumab over placebo in terms of efficacy while demonstrating good tolerability. Treatment-related adverse reactions did not differ significantly compared to placebo and dropout rates were minimal. The most commonly observed treatment-related adverse reaction was mild-to-moderate injection site reaction, described as erythema, pain, induration, or swelling at the injection site.

show abstract

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study

Cited by 10 publications

References 31 publications

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine

Contact Info

Product

Resources

About